Background: Concurrent chemoradiotherapy is the standard treatment for non-surgical care of patients with locally advanced oesophageal cancer. Nimotuzumab (h-R3) is a genetically engineered humanised monoclonal antibody that can recognise an epitope in the extracellular domain of human epidermal growth-factor receptor (EGFR). This phase 1 trial was designed to assess the safety and efficacy of nimotuzumab when given with concurrent chemoradiotherapy.

Methods: Patients age 18–75 years, with ECOG performance status 0–2 and locally advanced squamous oesophageal cancer confirmed by histological assay, were eligible for the study. Patients received radiotherapy to a total dose of 61.2 Gy/32Fx concurrent with two cycles of PF regimen (cisplatin 25 mg/m^2 days 1–3; fluorouracil 600 mg/m^2 continuous IV infusion days 1–3, every 28 days). An escalating weekly fixed dose of nimotuzumab (100, 200, and 400 mg) was administered during radiotherapy in a cohort study. After radiotherapy, patients received consolidation chemotherapy with PF regimen every 28 days for another two cycles. The primary endpoints were safety and early efficacy. The trial was approved by the Chinese State Food and Drug Administration and the protocol has passed ethical committee review and gained institutional review board permission. The trial is registered with clinicaltrials.gov, number NCT00950417. All participants gave written informed consent.

Findings: From July, 2009, to June, 2010, nine patients (seven men and two women) with a median age of 58 years (48–72 years) were enrolled. All patients tolerated the treatment. No adverse events likely to be related to nimotuzumab were noted. The objective remission rate, which can reflect early efficacy, was 66.67–75% based on the evaluable cases.

Interpretation: Nimotuzumab combined with chemoradiotherapy based on the PF regimen was safe and well-tolerated.

Funding: China National Twelfth Five-year Program Fund and Beijing Science Plan.

The authors declared no conflicts of interest.

doi:10.1016/j.ejcsup.2011.02.050

P50 DOSE-ESCALATION STUDY OF NIMOTUZUMAB PLUS IRI-NOTECAN AS SECOND-LINE TREATMENT IN METASTATIC COLORECTAL CANCER WITH WILD-TYPE K-RAS

J. Zhou, L. Shen, J. Zheng, Department of Internal Oncology, Beijing Cancer Hospital, Beijing, China. Biotech Pharmaceutical Co. Ltd., Beijing, China. Tongji University, School of Medicine, Shanghai, China

Background: Nimotuzumab is a humanised monoclonal antibody of epidermal growth-factor receptor (EGFR) monoclonal antibody, has demonstrated efficacy and an absence of severe skin toxicity in many phase 1 and 2 cancer trials.

Methods: We did a single-centre, randomised, parallel assignment, open-label study of nimotuzumab (N: 200 mg IV on days 1, 8, and 15, every 3 weeks) plus irinotecan (I: 180 mg/m^2 on day 1 every 2 weeks until progression, or adverse events, for a maximum of six cycles. Nimotuzumab was given as 200, 400, or 600 mg weekly until progression or adverse events. Primary endpoints were objective response rate and toxicity. Secondary endpoints were progression-free and overall survival. Patients gave written informed consent.

Findings: A total of 22 patients (male-to-female ratio 14:8; median age 55 years, range 30–78) were enrolled from July, 2009, to July, 2010. Four, seven, and 11 patients received nimotuzumab at a dose of 200, 400, and 600 mg, respectively. The total number of doses of nimotuzumab was 244 (median 6, range 2–30). No grade 3–4 toxic effects relating to nimotuzumab were observed. Two patients developed skin rash (grade 1): one each at the 400 and 600 mg doses. The maximum tolerated dose has not yet been reached. Three patients (two at the 400 mg dose and one at 600 mg) dropped out for personal reasons. In the 600 mg group, partial response was 40% (4/10) and progressive disease (PD) was 60% (6/10). In the 400 mg group, stable disease (SD) was 20% (1/5) and PD was 80% (4/5). In the 200 mg group, SD was 50% (2/4) and PD was 50% (2/4). Follow-up of overall survival is ongoing.

Interpretation: Addition of nimotuzumab 600 mg weekly to irinotecan for second-line treatment of mCRC is safe, and first data suggest promising activity. The maximum tolerated dose of nimotuzumab has not been reached yet.

Funding: Beijing Science Plan.

The authors declared no conflicts of interest.

doip:10.1016/j.ejcsup.2011.02.051

P51 RANDOMISED, SINGLE-CENTRE, PHASE 2 TRIAL OF NIMOTUZUMAB PLUS CISPLATIN AND S-1 AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER

Y. Chi, J. Wang, Z. Zheng, A. Zhou, L. Yang, T. Qu, W. Jiang, S. Shi, Y. Sun, Y. Song, S. Kang, J. Zheng, a, b, c

a Cancer Hospital, Chinese Academy Medical Science, Beijing, China. Biotech Pharmaceutical Co. Ltd., Beijing, China. c School of Medicine, Tongji University, Shanghai, China

Background: Nimotuzumab, a humanised anti-epidermal growth-factor receptor (EGFR) monoclonal antibody, has demonstrated efficacy and an absence of severe skin toxicity in many phase 1 and 2 cancer trials.

Methods: We did a single-centre, randomised, parallel assignment, open-label study of nimotuzumab (N: 200 mg IV on days 1, 8, and 15, every 3 weeks) plus cisplatin (C: 30 mg/m^2 on days 1 and 2, every 3 weeks) plus S-1 (S: 80 mg/m^2 twice daily on days 1–14, followed by 7 days off) versus cisplatin plus S-1, as first-line treatment in patients with advanced or metastatic gastric cancer. If tumour control was achieved, NCS and CS were continued until unacceptable toxicity or disease progression. The primary endpoint was objective response rate (ORR) and the secondary endpoints included time-to-progression (TTP), progression-free survival (PFS), 1-year survival rates, and safety.

Findings: 40 patients, 27 men and 13 women, with a median age of 54 years (range 21–74) and good performance status (ECOG PS 0–2) were treated with NCS (n = 20) or CS (n = 20). Up to January 14, 2011, 36 patients (NCS group 19 cases, CS group 17 cases) have undergone efficacy assessment. ORR was 63.2% (12/19) in the NCS group, 32% (5/16) in the CS group.